Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipid Sciences has concluded enrollment of new patients in the company's HDL therapy clinical trial currently being conducted at the Washington Hospital Center, Suburban Hospital, and Washington Adventist Hospital.
Subscribe to our email newsletter
The participants in this clinical trial were randomized 1:1 in the treatment and placebo arms of the study titled, “randomized, single-blind, placebo-controlled study to evaluate the safety of the Lipid Sciences’ selective delipidation system, PDS-2, in subjects with acute coronary syndrome (ACS).” Patients currently enrolled in the trial will have completed their scheduled plasma collection and re-infusion treatments by the end of January 2008.
Dr Lewis Meyer, president and CEO of Lipid Sciences, said: “The FDA approved protocol for this study permitted Lipid Sciences to enroll a maximum of 30 patients based on the expectation that there would be a drop-out rate of up to 33%. The unusually high retention rate of 92% that we have experienced in this trial has allowed the company to gather sufficient data based upon the current enrollment of 28 patients.”